Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Leukemia, Myelocytic, Acute
About this trial
This is an interventional treatment trial for Leukemia, Myelocytic, Acute focused on measuring Leukemia,Erythroblastic, Acute, Erythroblastic Leukemia, Acute, Leukemia, Myeloid, Acute, Myeloid Leukemia, Acute
Eligibility Criteria
Inclusion Criteria: Diagnosis of acute myeloid leukemia by immunophenotyping, morphology, and cytochemical staining; myelodysplasia; or biphenotypic leukemia. Age less than or equal to 21 years at time of study entry. No prior therapy for this malignancy (patients with secondary AML following treatment of primary malignancy are eligible) except for one dose of intrathecal therapy. Negative pregnancy test Patient does not have Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML) Exclusion Criteria: Positive pregnancy test Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML)
Sites / Locations
- Stanford University Medical Center
- Dana-Farber Cancer Institute
- Children's Hospital of Michigan (Wayne State University)
- St. Jude Children's Research Hospital
- Cook Children's Medical Center
- MD Anderson Cancer Center
- Texas Children's Cancer Center
- Seattle Children's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
HDAC (High-Dose Cytarabine)
LDAC (Low-Dose Cytarabine)
Since limited characters are allowed in this passage, please see detailed Description for HDAC.
Since limited characters are allowed in this passage, please see detailed Description for LDAC.